Reduced protein synthesis in schizophrenia patient-derived olfactory cells

Translational Psychiatry

Volumn 5, Issue 10, 2015, Pages

  English, J A ^a   Fan, Y ^b   Focking M ^a   Lopez, L M ^a   Hryniewiecka, M ^a   Wynne, K ^a   Dicker, P ^a   Matigian, N ^b   Cagney, G ^a   Mackay Sim, A ^b   Cotter, D R ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; CELL CULTURE; FEMALE; HUMAN; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; OLFACTORY MUCOSA; PHYSIOLOGY; PROTEIN SYNTHESIS; PROTEOMICS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; CELLS, CULTURED; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; OLFACTORY MUCOSA; PROTEIN BIOSYNTHESIS; PROTEOMICS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 85007538368     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.119     Document Type: Article

References (38)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–1442.
2. Mackay-Sim A. Concise review: patient-derived olfactory stem cells: new models for brain diseases. Stem Cells 2012; 30: 2361–2365.
3. Horiuchi Y, Kano S, Ishizuka K, Cascella NG, Ishii S, Talbot CC Jr et al. Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: utility and limitation of the surrogate tissues in research for brain disorders. Neurosci Res 2013; 77: 247–250.
4. Toritsuka M, Kimoto S, Muraki K, Landek-Salgado MA, Yoshida A, Yamamoto N et al. Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelop-mental deficits in a 22q11 deletion syndrome mouse model. Proc Natl Acad Sci USA 2013; 110: 17552–17557.
5. Kano S, Colantuoni C, Han F, Zhou Z, Yuan Q, Wilson A et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry 2013; 18: 740–742.
6. Mor E, Kano S, Colantuoni C, Sawa A, Navon R, Shomron N. MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients. Neurobiol Dis 2013; 55: 1–10.
7. Fan Y, Abrahamsen G, Mills R, Calderon CC, Tee JY, Leyton L et al. Focal adhesion dynamics are altered in schizophrenia. Biol Psychiatry 2013; 74: 418–426.
8. Fan Y, Abrahamsen G, McGrath JJ, Mackay-Sim A. Altered cell cycle dynamics in schizophrenia. Biol Psychiatry 2012; 71: 129–135.
9. Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K et al. Pheno-typic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry 2014; 20: 361–368.
10. Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, Nouwens A et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis Model Mech 2010; 3: 785–798.
11. English JA, Harauma A, Föcking M, Wynne K, Scaife C, Cagney G et al. Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus. Front Genet 2013; 4: 208.
12. Schilling B, Rardin MJ, MacLean BX, Zawadzka AM, Frewen BE, Cusack MP et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics 2012; 11: 202–214.
13. Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J et al. Using iRT, a normalized retention time for more targeted measurement of peptides. Pro-teomics 2012; 12: 1111–1121.
14. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45: 1150–1159.
15. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010; 11: 843–854.
16. Buffington SA, Huang W, Costa-Mattioli M. Translational control in synaptic plasticity and cognitive dysfunction. Annu Rev Neurosci 2014; 37: 17–38.
17. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet 2010; 87: 139–145.
18. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998; 55: 215–224.
19. Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 2003; 53: 1086–1098.
20. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68, image 45.
21. Focking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E et al. Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. Mol Psychiatry 2014; 20: 424–432.
22. De Rubeis S, Pasciuto E, Li KW, Fernandez E, Di Marino D, Buzzi A et al. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron 2013; 79: 1169–1182.
23. Yoon KJ, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z et al. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell 2014; 15: 79–91.
24. Abekhoukh S, Bardoni B. CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome. Front Cell Neurosci 2014; 8: 81.
25. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9: 3368–3382.
26. English JA, Pennington K, Dunn MJ, Cotter DR. The neuroproteomics of schizo-phrenia. Biol Psychiatry 2011; 69: 163–172.
27. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009; 61: 10–26.
28. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506: 179–184.
29. Pocklington AJ, O'Donovan M, Owen MJ. The synapse in schizophrenia. Eur J Neurosci 2014; 39: 1059–1067.
30. Donnelly N, Gorman AM, Gupta S, Samali A. The eIF2alpha kinases: their structures and functions. Cell Mol Life Sci 2013; 70: 3493–3511.
31. Rothenburg S, Seo EJ, Gibbs JS, Dever TE, Dittmar K. Rapid evolution of protein kinase PKR alters sensitivity to viral inhibitors. Nat Struct Mol Biol 2009; 16: 63–70.
32. Carter CS, Bullmore ET, Harrison P. Is there a flame in the brain in psychosis? Biol Psychiatry 2014; 75: 258–259.
33. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307–315.
34. Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci 2013; 16: 1537–1543.
35. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99: 467–472.
36. Stoica L, Zhu PJ, Huang W, Zhou H, Kozma SC, Costa-Mattioli M. Selective phar-macogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci USA 2011; 108: 3791–3796.
37. Bowling H, Zhang G, Bhattacharya A, Perez-Cuesta LM, Deinhardt K, Hoeffer CA et al. Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity. Sci Signal 2014; 7: ra4.
38. Buszczak M, Signer RA, Morrison SJ. Cellular differences in protein synthesis regulate tissue homeostasis. Cell 2014; 159: 242–251.